JP7204676B2 - 疾患の予防および治療用の化合物およびその使用 - Google Patents

疾患の予防および治療用の化合物およびその使用 Download PDF

Info

Publication number
JP7204676B2
JP7204676B2 JP2019562001A JP2019562001A JP7204676B2 JP 7204676 B2 JP7204676 B2 JP 7204676B2 JP 2019562001 A JP2019562001 A JP 2019562001A JP 2019562001 A JP2019562001 A JP 2019562001A JP 7204676 B2 JP7204676 B2 JP 7204676B2
Authority
JP
Japan
Prior art keywords
group
substituted
galectin
disease
group substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019562001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519625A (ja
JP2020519625A5 (enExample
Inventor
エリーザー・ゾマー
ピーター・ジー・トレーバー
ラファエル・ニール
シャロン・シェクター
ジョセフ・エム・ジョンソン
ライアン・ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Sciences LLC
Original Assignee
Galectin Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences LLC filed Critical Galectin Sciences LLC
Publication of JP2020519625A publication Critical patent/JP2020519625A/ja
Publication of JP2020519625A5 publication Critical patent/JP2020519625A5/ja
Application granted granted Critical
Publication of JP7204676B2 publication Critical patent/JP7204676B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H99/00—Subject matter not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2019562001A 2017-05-12 2018-05-11 疾患の予防および治療用の化合物およびその使用 Active JP7204676B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505544P 2017-05-12 2017-05-12
US62/505,544 2017-05-12
PCT/US2018/032349 WO2018209255A1 (en) 2017-05-12 2018-05-11 Compounds for the prevention and treatment of diseases and the use thereof

Publications (3)

Publication Number Publication Date
JP2020519625A JP2020519625A (ja) 2020-07-02
JP2020519625A5 JP2020519625A5 (enExample) 2021-07-26
JP7204676B2 true JP7204676B2 (ja) 2023-01-16

Family

ID=64105444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019562001A Active JP7204676B2 (ja) 2017-05-12 2018-05-11 疾患の予防および治療用の化合物およびその使用

Country Status (12)

Country Link
US (2) US11576924B2 (enExample)
EP (1) EP3621973A4 (enExample)
JP (1) JP7204676B2 (enExample)
KR (1) KR102626669B1 (enExample)
CN (1) CN110869378B (enExample)
AU (1) AU2018265571B2 (enExample)
BR (1) BR112019023722A2 (enExample)
CA (1) CA3062648A1 (enExample)
IL (1) IL270469B2 (enExample)
MX (1) MX392945B (enExample)
WO (1) WO2018209255A1 (enExample)
ZA (1) ZA201908165B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117883A1 (en) * 2018-12-06 2020-06-11 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
JP7547345B2 (ja) * 2018-12-27 2024-09-09 グリコミメティクス， インコーポレイテッド ガレクチン－３阻害性ｃ－グリコシド
EP3947407B1 (en) 2019-03-26 2024-06-12 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
CN115244045A (zh) * 2019-12-24 2022-10-25 糖模拟物有限公司 抑制半乳凝素-3的c-糖苷酮、醚和醇
US12275720B2 (en) 2020-05-05 2025-04-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2021231243A1 (en) 2020-05-11 2021-11-18 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
CN115768768A (zh) 2020-05-28 2023-03-07 百时美施贵宝公司 半乳凝素-3抑制剂
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
JP7844491B2 (ja) 2021-02-09 2026-04-13 イドルシア・ファーマシューティカルズ・リミテッド ヒドロキシヘテロシクロアルカン－カルバモイル誘導体
WO2022184755A1 (en) 2021-03-03 2022-09-09 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077397A2 (en) 2005-01-18 2006-07-27 Amura Therapeutics Limited Method of producing conjugate vaccines
WO2017152048A1 (en) 2016-03-04 2017-09-08 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812681A1 (de) * 1988-04-16 1989-11-02 Bayer Ag Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB9626450D0 (en) * 1996-12-20 1997-02-05 Oxford Glycosciences Uk Ltd Therapeutic compounds
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
AU2007319806A1 (en) 2006-11-15 2008-05-22 The Brigham And Women's Hospital, Inc. Therapeutic uses of TIM-3 modulators
US8697862B2 (en) 2008-05-16 2014-04-15 Galecto Biotech Ab Synthesis of galactoside inhibitors
ES2652488T3 (es) * 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
EA201270316A1 (ru) 2009-08-25 2012-09-28 БиДжи МЕДИСИН, ИНК. Галектин-3 и сердечная ресинхронизирующая терапия
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
CA2794066C (en) 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
CA2848711C (en) 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
CN104245717B (zh) 2011-12-28 2017-10-24 卡莱克汀医疗有限公司 用于治疗人类疾病的新型糖类药物的组合物
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (enExample) * 2012-10-31 2015-09-11 Galecto Biotech Ab
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
EP3125908A4 (en) 2014-03-10 2017-11-15 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders
US20170095496A1 (en) 2014-04-08 2017-04-06 Galecto Biotech Ab Galactoside inhibitors for new uses
JP6735680B2 (ja) 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
CA2970062C (en) * 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US10799522B2 (en) 2015-07-27 2020-10-13 Wayne State University Compositions and methods relating to galectin detection
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
CA3062649A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077397A2 (en) 2005-01-18 2006-07-27 Amura Therapeutics Limited Method of producing conjugate vaccines
WO2017152048A1 (en) 2016-03-04 2017-09-08 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURPHY, PV et al.，Development of Carbohydrate-Based Scaffolds for Restricted Presentation of Recognition Groups. Extension to Divalent Ligands and Implications for the Strcture of Dimerized Receptors，The Journal of Organic Chemistry，2003年，Vol. 68，pp. 5692-5704

Also Published As

Publication number Publication date
US20230132265A1 (en) 2023-04-27
IL270469A (enExample) 2019-12-31
AU2018265571B2 (en) 2022-09-29
WO2018209255A1 (en) 2018-11-15
EP3621973A4 (en) 2021-10-27
ZA201908165B (en) 2023-07-26
AU2018265571A1 (en) 2019-12-05
EP3621973A1 (en) 2020-03-18
US11576924B2 (en) 2023-02-14
CN110869378A (zh) 2020-03-06
JP2020519625A (ja) 2020-07-02
CA3062648A1 (en) 2018-11-15
IL270469B1 (en) 2023-03-01
KR20200016246A (ko) 2020-02-14
MX392945B (es) 2025-03-19
US20200155586A1 (en) 2020-05-21
BR112019023722A2 (pt) 2020-05-26
MX2019013537A (es) 2020-02-13
IL270469B2 (en) 2023-07-01
KR102626669B1 (ko) 2024-01-17
CN110869378B (zh) 2023-10-13

Similar Documents

Publication Publication Date Title
KR102626669B1 (ko) 질환의 예방 및 치료를 위한 화합물 및 이의 용도
JP2020519597A (ja) 全身性インスリン抵抗性障害の治療用化合物およびその使用
EP2807176B1 (en) Novel galactoside inhibitors of galectins
KR102692840B1 (ko) 의학적 장애의 예방 및 치료를 위한 화합물 및 이의 용도
WO2019089080A1 (en) Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
CN109071585B (zh) 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途
JP2021152069A (ja) ガレクチンの新規なガラクトシド阻害剤
BR112018067693B1 (pt) Selenogalactosídeos, seus usos, e composição
JP5234550B2 (ja) Ｖｄａｃ機能調節剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221228

R150 Certificate of patent or registration of utility model

Ref document number: 7204676

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250